To include your compound in the COVID-19 Resource Center, submit it here.

Lovenox sales decline

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said third quarter sales of Lovenox enoxaparin fell 26% to EUR 537 million ($732 million) compared to 3Q09

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE